Is a Correction Looming Ahead for Bristol-Myers Squibb Company (BMY) – News Heater
Home  »  Business   »  Is a Correction Looming Ahead for Bristol-Myers Sq...

Is a Correction Looming Ahead for Bristol-Myers Squibb Company (BMY)

Bristol-Myers Squibb Company (NYSE:BMY) went up by 1.58% from its latest closing price compared to the recent 1-year high of $78.61. The company’s stock price has collected -1.76% of loss in the last five trading sessions. The Wall Street Journal reported on 06/03/22 that Bristol-Myers to Buy Turning Point Therapeutics for $4.1 Billion

Is It Worth Investing in Bristol-Myers Squibb Company (NYSE :BMY) Right Now?

Bristol-Myers Squibb Company (NYSE:BMY) scored a price-to-earnings ratio above its average ratio, recording 26.20 x from its present earnings ratio. Plus, the 36-month beta value for BMY is at 0.47. Opinions of the stock are interesting as 11 analysts out of 21 who provided ratings for Bristol-Myers Squibb Company declared the stock was a “buy,” while 1 rated the stock as “overweight,” 6 rated it as “hold,” and 1 as “sell.”

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free.


The average price from analysts is $80.99, which is $7.11 above the current price. BMY currently public float of 2.13B and currently shorts hold a 1.55% ratio of that float. Today, the average trading volume of BMY was 14.98M shares.

BMY’s Market Performance

BMY stocks went down by -1.76% for the week, with a monthly drop of -4.22% and a quarterly performance of 3.87%, while its annual performance rate touched 10.98%. The volatility ratio for the week stands at 1.75% while the volatility levels for the past 30 days are set at 1.78% for Bristol-Myers Squibb Company. The simple moving average for the period of the last 20 days is -2.21% for BMY stocks with a simple moving average of 11.38% for the last 200 days.

Analysts’ Opinion of BMY

Morgan Stanley, on the other hand, stated in their research note that they expect to see BMY reach a price target of $64. The rating they have provided for BMY stocks is “Underweight” according to the report published on April 06th, 2022.

Goldman gave a rating of “Buy” to BMY, setting the target price at $72 in the report published on December 17th of the previous year.

BMY Trading at -3.00% from the 50-Day Moving Average

After a stumble in the market that brought BMY to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -6.16% of loss for the given period.

Volatility was left at 1.78%, however, over the last 30 days, the volatility rate increased by 1.75%, as shares sank -2.88% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -2.08% lower at present.

During the last 5 trading sessions, BMY fell by -1.76%, which changed the moving average for the period of 200-days by +12.10% in comparison to the 20-day moving average, which settled at $75.33. In addition, Bristol-Myers Squibb Company saw 18.32% in overturn over a single year, with a tendency to cut further gains.

Insider Trading

Reports are indicating that there were more than several insider trading activities at BMY starting from Caforio Giovanni, who sale 30,000 shares at the price of $74.04 back on Jun 13. After this action, Caforio Giovanni now owns 551,104 shares of Bristol-Myers Squibb Company, valued at $2,221,200 using the latest closing price.

LEUNG SANDRA, the EVP, General Counsel of Bristol-Myers Squibb Company, sale 65,000 shares at $74.89 during a trade that took place back on Jun 06, which means that LEUNG SANDRA is holding 308,627 shares at $4,867,850 based on the most recent closing price.

Stock Fundamentals for BMY

Current profitability levels for the company are sitting at:

  • +20.57 for the present operating margin
  • +57.69 for the gross margin

The net margin for Bristol-Myers Squibb Company stands at +15.08. Equity return is now at value 17.70, with 5.80 for asset returns.

The liquidity ratio also appears to be rather interesting for investors as it stands at 1.52.

Is Kimberly-Clark Corporation (KMB) a Keeper?

Kimberly-Clark Corporation (NYSE:KMB) went up by 3.54% from its latest closing price compared to the recent 1-year high of $145.79. The company’s stock price has